Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.
A, P., M, D.M., S, S., R, M., L, P., D, R., G, R., S, G., G, S., & M, M. (2026). Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.. Current cardiology reports. https://doi.org/10.1007/s11886-026-02405-0
A P, M DM, S S, R M, L P, D R, et al. Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.. Current cardiology reports. 2026; doi: 10.1007/s11886-026-02405-0
A P, M DM, S S, et al. Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.[J]. Current cardiology reports. 2026. DOI: 10.1007/s11886-026-02405-0.
@article{a2026,
author = {Palermi A and Di Marco M and Saraullo S and Magnano R and Pezzi L and Rossi D and Renda G and Gallina S and Sinagra G and Merlo M},
title = {Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.},
journal = {Current cardiology reports},
year = {2026},
doi = {10.1007/s11886-026-02405-0},
note = {PMID: 42658384},
}
TY - JOUR AU - Palermi A AU - Di Marco M AU - Saraullo S AU - Magnano R AU - Pezzi L AU - Rossi D AU - Renda G AU - Gallina S AU - Sinagra G AU - Merlo M TI - Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents. T2 - Current cardiology reports PY - 2026 DO - 10.1007/s11886-026-02405-0 AN - PMID:42658384 ER -
PURPOSE OF REVIEW: Antiarrhythmic drug therapy in cardiomyopathies remains challenging because arrhythmic risk, drug efficacy, and pro-arrhythmic vulnerability vary substantially across phenotypes. This review summarizes contemporary guideline and consensus recommendations on antiarrhythmic drug use in hypertrophic, dilated, non-dilated left ventricular, and arrhythmogenic cardiomyopathies. RECENT FINDINGS: Recent guidelines increasingly emphasize phenotype-oriented arrhythmia management, but specific recommendations for antiarrhythmic drug therapy remain fragmented. Beta-blockers and amiodarone are the most consistently recommended agents in structural heart disease, whereas class I drugs are generally restricted. Evidence is strongest for hypertrophic and arrhythmogenic cardiomyopathies, while recommendations for dilated and non-dilated left ventricular cardiomyopathies are largely extrapolated from broader heart failure populations. Antiarrhythmic drugs are mainly used to reduce arrhythmic burden, symptoms, and implantable cardioverter-defibrillator therapies rather than to improve survival. Future studies should define phenotype-specific strategies based on ventricular function, myocardial scar, genotype, and clinical context.